PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
118.91%
Cash & equivalents yoy growth 1.25-1.5x CRVO's 98.90%. Bruce Berkowitz would examine if higher cash accumulation is strategic or just idle.
No Data
No Data available this quarter, please select a different quarter.
118.91%
Cash + STI yoy 1.25-1.5x CRVO's 98.90%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
104.59%
Below half of CRVO's -37.08%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
15.06%
≥ 1.5x CRVO's 1.06%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Higher Other Non-Current Assets Growth compared to CRVO's zero value, indicating worse performance.
15.06%
Below half of CRVO's -38.18%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
104.51%
Below half of CRVO's -37.98%. Michael Burry sees a potential red flag for stagnation or capital shortage.
55.57%
Above 1.5x CRVO's 23.84%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
719.98%
1.25-1.5x CRVO's 514.37%. Martin Whitman sees a potentially higher near-term liability load.
14812.60%
Above 1.5x CRVO's 108.92%. Michael Burry sees a red flag for liquidity risk vs. competitor.
-100.00%
Higher Long-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
4364.90%
Above 1.5x CRVO's 108.92%. Michael Burry sees a potential leverage warning sign.
91.77%
Less than half of CRVO's -99.01%. David Dodd sees fewer share issuances vs. competitor.
-19849.13%
≥ 1.5x CRVO's -9.99%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1201.65%
Below half CRVO's -204.88%. Michael Burry sees potential underperformance in building shareholder capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
92.16%
Above 1.5x CRVO's 16.86%. Michael Burry sees a major jump. Investigate leverage rationale.
-119.69%
Less than half of CRVO's 12.93%. David Dodd sees better deleveraging or stronger cash buildup than competitor.